Eris Lifesciences Limited Share Price Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Delayed Bombay S.E. 02:49:44 05/07/2024 pm IST 5-day change 1st Jan Change
1,015 INR -1.57% Intraday chart for Eris Lifesciences Limited -1.22% +11.15%
Sales 2024 20.09B 241M Sales 2025 * 29.73B 356M Capitalization 140B 1.68B
Net income 2024 3.92B 46.96M Net income 2025 * 4.08B 48.87M EV / Sales 2024 6.37 x
Net Debt 2024 13.35B 160M Net Debt 2025 * 25.27B 303M EV / Sales 2025 * 5.57 x
P/E ratio 2024
29.3 x
P/E ratio 2025 *
34.8 x
Employees 3,548
Yield 2024 *
0.69%
Yield 2025 *
0.67%
Free-Float 27.63%
More Fundamentals * Assessed data
Dynamic Chart
Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals MT
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel. CI
Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit MT
Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale MT
Transcript : Eris Lifesciences Limited, Q4 2024 Earnings Call, May 21, 2024
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million RE
Eris Lifesciences Limited agreed to acquire additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel for INR 2.4 billion. CI
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion. CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited. CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026 CI
More news
1 day-1.81%
1 week-1.22%
Current month-1.22%
1 month+10.21%
3 months+19.21%
6 months+8.45%
Current year+11.15%
More quotes
1 week
1 012.10
Extreme 1012.1
1 089.85
1 month
913.65
Extreme 913.65
1 089.85
Current year
810.10
Extreme 810.1
1 089.85
1 year
686.35
Extreme 686.35
1 089.85
3 years
550.90
Extreme 550.9
1 089.85
5 years
341.05
Extreme 341.05
1 089.85
10 years
341.05
Extreme 341.05
1 089.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 27/07/27
President - 01/10/01
Director of Finance/CFO 44 01/13/01
Members of the board TitleAgeSince
Director/Board Member 53 05/21/05
Director/Board Member 44 30/18/30
Chief Executive Officer 50 27/07/27
More insiders
Date Price Change Volume
05/24/05 1,015 -1.57% 5 047
04/24/04 1,031 -1.13% 3,485
03/24/03 1,042 +0.35% 2,765
02/24/02 1,039 -1.08% 20,518
01/24/01 1,050 +2.51% 6,817

Delayed Quote Bombay S.E., July 05, 2024 at 02:49 pm IST

More quotes
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,030 INR
Average target price
1,092 INR
Spread / Average Target
+5.97%
Consensus

Quarterly revenue - Rate of surprise